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p53-reactivating moleculesPancreatic adenocarcinoma (PDAC) is the fourth leading cause of cancer-related deathsworldwide; PDAC is char-
acterized by poor prognosis, resistance to conventional chemotherapy and high mortality rate. TP53 tumor sup-
pressor gene is frequently mutated in PDAC, resulting in the accumulation of mutated protein with potential
gain-of-function (GOF) activities, such as genomic instability, hyperproliferation and chemoresistance. The pur-
pose of this study was to assess the relevance of the p53 status on the PDAC cells response to the standard drug
gemcitabine. We also examined the potential therapeutic effect of p53-reactivatingmolecules to restore themu-
tant p53 function in GEM treated PDAC cells. We showed that gemcitabine stabilized mutant p53 protein in the
nuclei and induced chemoresistance, concurrent with themutant p53-dependent expression of Cdk1 and CCNB1
genes, resulting in a hyperproliferation effect. Despite the adverse activation of mutant p53 by gemcitabine, si-
multaneous treatment of PDAC cells with gemcitabine and p53-reactivating molecules (CP-31398 and RITA) re-
duced growth rate and induced apoptosis. This synergistic effectwas observed in bothwild-type andmutant p53
cell lines and was absent in p53-null cells. The combination drug treatment induced p53 phosphorylation on
Ser15, apoptosis and autophagosome formation. Furthermore, pharmacological inhibition of autophagy further
increased apoptosis stimulated by gemcitabine/CP-31398 treatment. Together, our results show that
gemcitabine aberrantly stimulates mutant p53 activity in PDAC cells identifying key processes with potential
for therapeutic targeting. Our data also support an anti-tumoral strategy based on inhibition of autophagy com-
bined with p53 activation and standard chemotherapy for both wild-type and mutant p53 expressing PDACs.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Pancreatic adenocarcinoma (PDAC) is the fourth leading cause of
cancer-related deaths worldwide and one of the most aggressive and
devastating human malignancies [1]. Because early symptoms of the
disease are extremely rare, most patients present locally advanced dis-
ease and/or metastasis at the time of diagnosis, which prevents them
from being considered as candidates for surgery. Standard treatments
for advanced disease include monotherapy with gemcitabine (2′,2′-
diﬂuoro-2′-deoxycytidine; GEM) with a response rate of less than 20%
[2]. Therefore, the identiﬁcation of effective targets and novel therapeu-
tic strategies to improve GEM effects in PDAC have been the topic ofcogenomic Unit, Regina Elena
3 00144 Rome, Italy. Tel.: +39
production Sciences, Section of
37134 Verona, Italy. Tel.: +39
assimo.donadelli@univr.itextensive investigation in the last few years [3]. The p53 tumor suppres-
sor gene ismutated inmore than 50%of human cancers, including PDAC
(50–75%), while the remaining 50% of tumors exhibit alterations in
pathways regulating p53 functions [4–6]. Mutant p53 proteins
(mp53) are incapable of recognizingwild-type p53 (wt p53) DNA bind-
ing sites in the promoter of p53 target genes and furthermore, some
mutations acquire new and distinct oncogenic properties, which is gen-
erally referred to as “gain of function” (GOF) [7]. In particular, mp53 can
reach the promoter of target genes through the interaction with
sequence-speciﬁc transcription factors, such as NF-Y, E2F1, NF-kB and
the Vitamin D receptor (VDR) [8–10]. Mutant p53 proteins have been
shown to interfere with regulation of cell survival, DNA damage repair
and drug resistance [11–14]. Therefore, activation of mp53-dependent
pathways plays critical roles in tumor development, drug resistance
and metastasis [15–18]. During the last few years, several attempts to
identify p53-activating compounds have been made employing anti-
body assays and cell-based screening approaches [19]. These studies
led to the identiﬁcation of small molecules, such as CP-31398 and
RITA, which have been shown to re-establish the wild-type transcrip-
tionally competent conformation of mp53 proteins [20]. These
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carrying tumors and to induce apoptotic cell death [21–25]. Recently,
we showed that p53-reactivating molecules could inhibit the prolifera-
tion of pancreatic adenocarcinoma cells bearing mp53 and that their
effect was attenuated by an AMPK/p53-mediated cyto-protective au-
tophagy [26]. In this study, we have characterized, at the molecular
level, the induction of mp53 transcriptional GOF activity with the asso-
ciated chemioresistance in PDAC cell lines treated with the standard
chemotherapeutic drug GEM. We also analyzed the effect of GEM in
combination with CP-31398 and RITA in PDAC cell lines expressing wt
or mp53. Our results revealed a novel role of mp53 protein in the aber-
rant regulation of the cell cycle in response to DNA-damaging agents in
PDAC cells.2. Materials and methods
2.1. Chemicals
Gemcitabine (2′,2′-diﬂuoro-2′-deoxycytidine; GEM) was provided
by Accord Healthcare (Milan, Italy) and CP-31398 dihydrochloride
hydrate was obtained from Sigma (Milan, Italy). Both compounds
were solubilized in sterile water. RITA [5,5′-(2,5-furandiyl)bis-2-
thiophenemethanol; reactivation of p53 and induction of tumor cell ap-
optosis] was obtained from Sigma (Milan, Italy) and solubilized in
DMSO. Chloroquine diphosphate [CQ; N4-(7-chloro-4-quinolinyl)-N1,
N1-dimethyl-1,4-pentanediamine], and 3-methyladenine (3MA) were
obtained from Sigma (Milan, Italy).2.2. Cell culture
PaCa3 (wt p53), Panc1 (mp53-R273H), PaCa44 (mp53-C176S), Mia
PaCa2 (mp53-R248W), SUIT-2 (mp53-R273H) and ASPC-1 (p53-null)
human PDAC cell lines were grown in RPMI 1640 supplemented with
2 mM glutamine (Life Technologies, Milan, Italy), 10% FBS, and
50 μg/ml gentamicin sulfate (BioWhittaker, Lonza, Bergamo, Italy).
Cell lines were incubated at 37 °C with 5% CO2.2.3. Cell proliferation assay
Cells were seeded in 96-well plates (5 × 103 cells/well) and the day
after were incubated with various compounds at the indicated times
(see Figure legends). At the end of the treatments, cell growthwasmea-
sured by Crystal Violet assay (Sigma, Milan, Italy) according to the
manufacturer's protocol and absorbance measured by spectrophoto-
metric analysis (A595nm).2.4. RNA extraction and qPCR
Total RNA was extracted using TRIzol Reagent (Invitrogen, Milan,
Italy). One μg RNAwas reverse transcribed using ﬁrst-strand cDNA syn-
thesis. RT-qPCRwas performed in triplicate samples by SYBR Green de-
tection chemistry with SYBR Green PCR Master Mix (Applied
Biosystems) on a 7000 Sequence Detection System (Applied
Biosystems). The following oligonucleotide sequences used were:
hCdk1-forward, 5′-GGAAGGGGTTCCTAGTACTGC-3′ and Rev 5′- TGGA
ATCCTGCATAAGCACA-3′; hCCNB1-forward 5′-GTTCCTACGGCCCCTG
CT-3′ and Rev 5′-ATTTTGGCCTGCAGTTGTTC-3′; and GAPDH-forward
5′-TGTGTCCGTCG TGGATCTGA-3′ and Rev 5′-R-GATGCCTGCTTCACCA
CCTT-3′. The following cycling conditions were used: 95 °C for 10 min,
40 cycles at 95 °C for 15 s, 60 °C for 1 min, and 72 °C for 30 s. The aver-
age of cycle threshold of each triplicate was analyzed according to the
2(−ΔΔCt) method.2.5. Transient transfection assays
Exponentially growing cells were seeded at 5 × 103 cells/well in 96-
well plates and at 2.5 × 105 cells in 60 mm cell culture plates for prolif-
eration assays and protein extraction respectively. To over-express
mp53 in ASPC-1 p53-null cells, transfections were carried out using
pcDNA3-mutp53R273H expression vector or its relative negative
control (pcDNA3) [27]. Wt p53 and mp53 protein expression was
transiently knocked-down by transfection with pRSUPER-p53 vector
or its negative control (pRSUPER), kindly provided by Reuven Agami
(The Netherlands Cancer Institute, Amsterdam) [28]. The knock-down
of Beclin1 expression was obtained by transfecting cells with a speciﬁc
Beclin1 siRNA: 5′-ACAGUGAAUUUAAACGACAGCAGCU-3′ and 5′-
AGCUGCUGUCGUUUAAAUUCACUGU-3′ and with a siRNA-CTRL (nega-
tive control): 5′-CAGUCGCGUUUGCGACUGG-3′ purchased from Life
Technologies (Monza MB, Italy). Cells were transfected by siRNAs at a
ﬁnal concentration of 50 nM using Lipofectamine 2000 (Life Technolo-
gies) for 24 h, according to the manufacturer's instructions. At the end
of transfection time, the culture medium was changed and cells were
treated with the compounds indicated in Figure Legends.
2.6. Drug combination studies
Drug combination studies were performed using the concentration
ratios [GEM]:[CP-31398] = 1:8 and [GEM]:[RITA] = 1:16, which were
chosen on the basis of GEM, CP-31398, or RITA IC50mean values. Taking
into account the drug molar ratios, the ranges of concentration used
were 50–2000 nM for GEM, 0.4–16 μM for CP-31398 and 0.8–32 μM
for RITA. The Combination Index (CI) was calculated by the Chou–
Talalay equation [29], which takes into account both the potency
(IC50) and the shape of the dose–effect curve, taking advantage of the
CalcuSyn software (Biosoft, Cambridge, UK). The general equation for
the classic isobologram is given by CI = (D)1/(Dx)1 + (D)2/(Dx)2 +
[(D)1 · (D)2]/[(Dx)1.(Dx)2], where (Dx)1 and (Dx)2 in the denomina-
tor are doses (or concentrations) for D1 (drug 1) and D2 (drug 2) alone
that gives x% growth inhibition, whereas (D)1 and (D)2 in the numera-
tors are the doses of drug 1 and drug 2 in combination that also inhibit
x% cell growth (i.e., isoeffective). CI/effect curves represent the CI versus
the fraction (0–1) of cells killed bydrug combinations: CI values below1
indicate a synergistic effect of the drug combination. Dose Reduction
Index (DRI25, DRI50, and DRI75) represents the folds of dose reduction
to obtain 25%, 50%, or 75% cell growth inhibition in combination setting
as compared to each drug alone. In all the experiments, we obtained a
linear correlation coefﬁcient (r) N 0.90.
2.7. Immunoblot analysis
For total cell extracts, cells were harvested, washed in PBS, and re-
suspended in lysis buffer in the presence of phosphatase and protease
inhibitors (50 mM Tris–HCl pH 8, 150 mM NaCl, 1% Igepal CA-630,
0.5% Na-Doc, 0.1% SDS, 1 mM Na3VO4, 1 mM NaF, 2.5 mM EDTA,
1 mM PMSF, and 1× protease inhibitor cocktail). After three freeze/
thaw cycles and incubation on ice for 30 min, the lysates were centri-
fuged at 14,000 × g for 10 min at 4 °C and the supernatant fractions
were used forWestern blot analysis. Nuclear extracts were prepared ac-
cording to Osborn and colleagues [30]. Protein concentration was mea-
sured by Bradford reagent (Pierce, Milan, Italy) using bovine serum
albumin as a standard. Protein extracts (50 μg/lane) were resolved on
a 12% SDS-polyacrylamide gel and electro-blotted onto PVDF mem-
branes (Millipore, Milan, Italy). Membranes were blocked in 5% low-
fat milk in TBST (50 mM Tris pH 7.5, 0.9% NaCl, 0.1% Tween 20) for 1 h
at room temperature and probed overnight at 4 °Cwith amousemono-
clonal anti-phospho (Ser15) p53 (1:1500 in blocking solution) (Cell
Signaling, # 9286), mouse polyclonal anti-p53 (1:500) (Santa Cruz, sc-
263), mouse monoclonal anti-TATA-box-binding protein (TBP)
(1:500) (Merck-Millipore, SL-30-3-563), rabbit monoclonal anti-LC3
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(1:1000) (GeneTex, # GTX113039), or rabbit monoclonal glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) (1:1000) (Cell Signaling,
# 5174S). Horseradish peroxidase conjugated anti-mouse or anti-
rabbit IgGs (1:8000 in blocking solution) (Upstate Biotechnology,
Milan, Italy) were used as secondary antibodies. Immunodetection
was carried out using chemiluminescent substrates (Amersham
Pharmacia Biotech, Milan, Italy) and recorded using a HyperﬁlmECL
(Amersham Pharmacia Biotech). ECL results were scanned and the
amount of each protein band quantitated using NIH Image J software
(http://rsb.info.nih.gov/nih-image/). Blots were probed with GAPDH
as a loading control and the amount of each protein was normalized
to the amount of GAPDH detected in the same extract.2.8. Apoptosis assay
Cells were seeded in 96-well plates (5× 103 cells/well). Twenty-four
hours later, cells were treated with various compounds at concentra-
tions indicated in Figure legends for 48 h. At the end of the treatment,
cells were ﬁxed with 2% paraformaldehyde in PBS for 30 min at room
temperature, washed twice with PBS and stained with annexinV/FITCPanc1  PaCa3
- +              - +       GEM
P-p53
GAPDH
p53
P-
p5
3 
an
d 
p5
3 
pr
ot
ei
n
ex
pr
es
si
on
(fo
ld
in
du
ct
io
n)
 
A B
Panc1  PaCa3
- +              - +       GEM
P-p53
p53
TBP
C
P-
p5
3 
an
d 
p5
3 
pr
ot
ei
n
ex
pr
es
si
on
(fo
ld
in
du
ct
io
n)
 
D
Fig. 1. Effect of GEM on mutant and wt p53 expression, phosphorylation, and nuclear localizat
nuclear extracts (C and D) were used for western blot analyses with p53 antibodies (total and
purity of the extracts. The amount of protein in each extract was quantitated using NIH image
*p b 0.05 GEM versus CTRL in both Panc1 and PaCa3 cells.(Bender MedSystem, Milan, Italy) in binding buffer (10 mM HEPES/
NaOH pH 7.4, 140mMNaCl, and 2.5mMCaCl2) for 10min at room tem-
perature in the dark. Cells were then washed with binding buffer and
ﬂuorescence was measured using a multimode plate reader (Ex485nm
and Em535nm) (GENios Pro, Tecan, Milan, Italy). The values were nor-
malised on cell proliferation by Crystal Violet assay.2.9. Autophagosome formation assay
To quantify the induction of autophagy, cells were incubated with
the ﬂuorescent probe monodansylcadaverine (MDC; Sigma, Milan,
Italy). MDC is a selective marker for acidic vesicular organelles (AVOs),
such as autophagic vacuoles and autolysosomes. Brieﬂy, cells were
seeded in 96-well plates (5 × 103 cells/well) and treated with various
compounds as indicated in Figure legends. At the end of the treatments,
cells were incubated in culture medium containing 50 μMMDC at 37 °C
for 15 min. Cells were then washed with Hanks buffer (20 mM Hepes
pH 7.2, 10 mM glucose, 118 mM NaCl, 4.6 mM KCl, and 1 mM CaCl2)
and ﬂuorescence was measured using a multimode plate reader
(Ex340nm and Em535nm) (GENios Pro, Tecan, Milan, Italy). The values
were normalised on cell proliferation by Crystal Violet assay.- +      - +      - +      - + GEM
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ion. Panc1 and PaCa3 cells were treated with 5 μM GEM for 24 h. Whole-cell (A and B) or
phosphor serine 15). GAPDH (B) or TBP (D) were used loading controls and to verify the
J software and normalized to the amount of GAPDH or TBP protein in the same extract.
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ANOVA analysis was performed by GraphPad Prism 5 software.
P value b 0.05 was indicated as statistically signiﬁcant. Values are the
means of three independent experiments (±SD).3. Results
3.1. GEM induces phosphorylation and nuclear stabilization of both wt and
mutant p53
To investigate whether GEM treatment modiﬁed the phosphoryla-
tion state of p53 protein, we incubated Panc1 and PaCa3 cell lines, ex-
pressing mp53R273H and wt p53 protein, respectively, with 5 μM
GEM for 24 h. Fig. 1A and B show that GEM treatment induced Ser15
phosphorylation of both mutant and wt p53 proteins whereas their
total protein levels remained unchanged. Western blot analysis of the
nuclear extracts from both cell lines revealed that GEM stabilized the
nuclear pool of bothmutant andwt p53proteins (and their correspond-
ing Ser15-phosphorylated forms) (Fig. 1C and D). The purity of the nu-
clear extracts was conﬁrmed by western blot using anti-nuclear TATA-
box-binding protein (TBP) antibodies (Fig. 1C and D).Panc1A
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Fig. 2. Role of the p53 status on the expression level of CdK1 and CCNB1mRNAs in control and
described in “Materials andMethods” section. (A) Panc1 and PaCa3 cells were transfectedwith t
5 μM GEM for 24 h. CdK1 and CCNB1 mRNA level were normalized to GAPDH mRNA. Statistica
(B) Panc1 and PaCa3 cells were transfected as described in (A) whereas ASPC-1 cells were tran
were normalized to GAPDH mRNA. *p b 0.05.3.2. GEM induces mutant p53 target genes
It has been previously reported that the expression of some cell
cycle-related NF-Y target genes has aberrantly increased bymp53 in re-
sponse to adriamycin treatment [27]. This prompted us to investigate
whether the incubation of pancreatic cancer cells with GEM couldmod-
ulate the expression of cell cycle target genes. We observed signiﬁcant
increases in the mRNA expression levels of CdK1 and CCNB1 genes
after GEM treatment in Panc1 (mp53) cells while they were signiﬁcant-
ly decreased in PaCa3 (wt p53) cells (Fig. 2A). To evaluate the contribu-
tion of endogenous mp53 to these cell cycle genes induction, Panc1
cancer cells were transiently transfected with pRSUPER (control) and
pRSUPER-p53 to down-regulatemp53 expression as described inMate-
rial and Methods. Mutant p53 knock-down (KD) completely rescued
CdK1 and CCNB1 gene induction by GEM in Panc1 cells, indicating that
the activation of cell cycle genes by GEM was mediated by mp53
(Fig. 2A). On the other hand, the depletion of wt p53 expression in
PaCa3 cells signiﬁcantly increased CdK1 and CCNB1 gene expression, in-
dicating the repressive role of the wt p53 on gene expression after GEM
treatment (Fig. 2A). Overall, these ﬁndings are in agreementwith previ-
ous data showing that DNA damage-induced p53 accumulation in wt
p53 cells is critical for the cellular response to DNA damage [31,32]. Ac-
cordingly, mp53 depleted Panc1 cells showed decreases in CdK1 andPaCa3
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transfected with the mp53 (R273H) expression plasmid showed a sig-
niﬁcant increase in CdK1 and CCNB1 gene expression (Fig. 2B). Notably,
depletion of wt p53 expression in PaCa3 cells led to the induction of50
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To further evaluate whether the mp53 Cdk1 and CyclinB target genes
may be differentially expressed in pancreatic adenocarcinoma tissues,
we queried public gene expression data repositories (GEO datasets-
NCBI). The explorative analysis of the dataset fromZhang and colleagues
[33] revealed that CdK1 and CCNB2 transcripts were substantially up-
regulated in 45 pancreatic adenocarcinoma tissues, known to have a
high frequency (ranging from 50% to 75%) of mutations in TP53 gene,
compared to their matched normal pancreas samples (Suppl. Fig. 1).
3.3. Dual opposite role of mutant and wt p53 on cell growth inhibition and
apoptosis mediated by GEM
To investigate the functional role of mutant and wt p53 on PDAC
cells response to GEM we evaluated the proliferation rate and the cell
death in Panc1 andPaCa3 cells (Fig. 3A andB). Intriguingly, we observedPanc1                         
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Fig. 4.Effect of GEMandCP-31398 onCdK1 and CCNB1mRNAexpression, p53 expression andp
40 μM CP-31398 for 24 h. CdK1 and CCNB1 expression was determined by qRT-PCR and norma
cells were treatedwith 5 μMGEM and/or 40 μMCP-31398 for 48 h.Whole-cell extracts were pr
ing control. (C) Quantitative evaluation of P-p53 and p53 in Panc1 and PaCa3 cells treated as dthat silencing of mutant or wt p53 had a dual and opposite role on cells
response to GEM: mp53 KD strongly sensitized cancer cells to GEM
treatment overcoming drug resistance (Fig. 3C), while wt p53 KD res-
cued the anti-proliferative effect of GEM (Fig. 3D). To ameliorate these
results, we tested the effect of GEM with and without mp53 KD in
other PDAC cell lines (PaCa44, MiaPaCa2, and SUIT-2) bearing different
TP53 gene mutations (see Material and Methods). In all of these cell
lines we observed that mp53 KD strongly sensitized cancer cells to
GEM treatment (Suppl. Fig. 2A, 2B, and 2C) and to GEM-stimulated ap-
optosis (Suppl. Fig. 3). Moreover, the ectopic expression of mp53
(R273H) protein in ASPC-1 cell line (p53 null) strongly inhibited the ef-
fect of GEM treatment (Fig. 3E and F). Similarly, we observed thatmp53
KD stimulated GEM-mediated apoptosis, whereas wt p53 KD repressed
GEM-mediated apoptosis (Fig. 3G). Finally, mp53 over-expression in
p53-null ASPC1 cells completely suppressed apoptosis by GEM treat-
ment (Fig. 3H).       PaCa3
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95C. Fiorini et al. / Biochimica et Biophysica Acta 1853 (2015) 89–1003.4. The p53-reactivating molecule CP-31398 blocks induction of mutant
p53-related genes by GEM treatment
To overcome the chemoresistance to GEM treatment in PDAC cells
expressing mp53 protein, we used the p53-reactivating molecule CP-
31398 and analyzed the expression of CdK1 and CCNB1 genes. CP-
31398 is able to stabilize a wt-like conformation of themutant p53 pro-
teins [22]. Incubation of Panc1 cells with CP-31398 in combinationwith
GEM, strongly inhibited themp53 target gene expression relative to thece
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Fig. 5. Growth inhibitory effect of GEM and p53-reactivating molecules (CP-31398 or RITA). Pa
2.5 μMGEM and/or 20 μMCP-31398 (molar ratio 1:8) for 48 h (A) orwith 2.5 μMGEM and/or 4
colorimetric assay. *p b 0.05. (C-F) CI/fractional effect curves obtained by CalcuSyn software fo
tional effect (x-axis) is the % of cell growth inhibition given by each drug combinationmaintaini
obtained by the same combinations are reported on the y-axis. CIs b 1 indicate synergistic effe
based on the previously determined IC50 mean values of GEM, CP-31398, or RITA. (G and H)
RITA. DRI25 DRI50, and DRI75 indicate the fold reduction of GEM concentration in combination se
respectively. *p b 0.05.cells incubated with GEM alone. The drug combination signiﬁcantly
inhibited Cdk1 and CCNB1 gene expression in PaCa3 cells relative to
GEM or CP-31398 treatment alone (Fig. 4A). To further address this
issue, we analyzed p53 and P-p53 protein expression after GEM with
or without CP-31398 treatment in both mutant and wt p53 cell lines.
We observed that cells incubatedwith both GEMand CP-31398 showed
an increase in the phosphorylation of Ser15 residue of p53 compared to
untreated or single drug treated cells (Fig. 4B and C). The expression of
total p53 protein did not change by any of these treatments (Fig. 4B andce
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nc1 and PaCa3 cells were seeded in 96-well plates, incubated overnight, and treated with
0 μMRITA (molar ratio 1:16) for 48 h (B). Cell proliferationwasmeasured by Crystal Violet
r Panc1 and PaCa3 cells treated with GEM/CP-31398 or GEM/RITA combinations. The frac-
ng the samemolar ratio and increasing drug concentrations. Combination index (CI) values
cts. 1:8 molar ratio of GEM/CP-31398 and the 1:16 molar ratio of GEM/RITA were chosen
Dose Reduction Index (DRI) values of GEM when used in combination with CP-31398 or
ttings as compared to GEM alone in order to obtain 25%, 50%, or 75% cell growth inhibition,
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stimulate mp53 GOF activity and that the p53-reactivating molecules
can reverse this stimulation and increase wt p53-like activity in cancer
cells bearing mp53. In contrast, in cancer cells bearing wt p53, treat-
ment with p53-reactivating molecules can further stimulate p53
activity.
3.5. GEM and p53-reactivating molecules synergistically inhibit pancreatic
cancer cell proliferation
The antiproliferative effect of GEM in combination with each one of
the two p53-reactivating molecules CP-31398 and RITA, was examined
on Panc1 and PaCa3 cell lines. In both cell lines, treatment with CP-
31398 or RITA in combination with GEM signiﬁcantly decreased cell
growth as compared to single treatments (Fig. 5A and B). To evaluate
the potential synergistic effect of GEM treatment in combination with
CP-31398 or RITA, we analyzed cell growth inhibition curves using
CalcuSyn software (see Materials and Methods). Based on the software
requirements, in these experiments, we increased the treatment period
to 48 h in order to avoid proliferation exceeding 100% as we noted ear-
lier with 24 h GEM treated Panc1 cells (see Fig. 3C). Fig. 5C- F show a
dose-dependent growth analyses in cells treatedwith different concen-
trations of GEM and/or p53-reactivating molecules for 48 h. The results
of these analyses showed that the combination treatment induced a sig-
niﬁcant synergistic antiproliferative effect in cancer cells as revealed by
the curves of the combination index (CI) values versus the fraction
(0–1) of cells killed by the combination drug treatment (Fig. 5C- F).
The b1 CI values represented a synergistic effect at both low and high
concentrations of the drugs. The CI50 values were 0.41 and 0.51 for
GEM/CP-31398 combination and 0.28 and 0.49 for GEM/RITA combina-
tion in Panc1 and PaCa3, respectively (Table. 1). To better describe the
antiproliferative synergism between GEM and p53-reactivating mole-
cules, Table 1 also includes the reduction folds related to the drug con-
centration to obtain 50% cell growth inhibition in combination setting
as compared to each drug alone (DRI50). Intriguingly, these analyses
showed that DRIs of GEM/CP-31398 and GEM/RITA combination treat-
ments were much higher in mp53 Panc1 cells than in wt p53 PaCa3
cells (Fig. 5G and H). This suggest that, despite the synergistic effect of
combination drug treatment in both cell types, patients bearing
mTP53 gene may beneﬁt more from this treatment regimen than
those bearing wt TP53 gene. Of note, no synergistic effects of combina-
tion drug treatment was observed in the p53-null ASPC-1 cell line
(Suppl. Fig. 4A and 4B), suggesting that this combinatory drug approach
could be ineffective in patients with TP53 gene deleted.
3.6. GEM and p53-reactivating molecules strongly induce apoptosis and
autophagy
CP-31398 or RITA treatments have been reported to have a signiﬁ-
cant effect on apoptotic cell death and induction of autophagy in tumour
cells [26,34]. To investigate the possible effects of GEM/CP-31398 com-
bined treatment in apoptosis and autophagy, we analyzed the apoptoticTable 1
Combination Index (CI) and Dose Reduction Index (DRI) values for GEM/CP-31398 or GEM/RIT
CELL LINES Molar Ratio
Panc1 GEM:CP 1:8
PaCa3 GEM:CP 1:8
Panc1 GEM:RITA 1:16
PaCa3 GEM:RITA 1:16
CI50 was calculated for 50% cell growth inhibition in the combined treatment by isobologram an
to obtain 50% cell growth inhibition in combination setting as compared to each drug alone.response (annexinV-FITC binding) and the amount of autophagosome
formation (monodansylcadaverine staining) in both Panc1 and PaCa3
cell lines treated with GEM and/or CP-31398 for 48 h. The combined
GEM/CP-31398 treatment led to induction of both apoptosis and au-
tophagy at much higher levels than that observed with the single treat-
ments (Fig. 6A and B). The induction of autophagy was further
conﬁrmed by examining the level of LC3 protein in the drug-treated
cultures of Panc1 and PaCa3 cells using an anti-LC3 antibody. The level
of LC3-II protein, the phosphoethanolaminated active form of the
autophagosome protein LC3-I, was signiﬁcantly increased after GEM/
CP-31398 combination treatment (Fig. 6C). This result supports the
formation of autophagosomes, which, after fusion with lysosomes, con-
stituted acidic vesicular organelles (AVOs) and were detected by
monodansylcadaverine staining (Fig. 6B).
3.7. Autophagy induced by GEM/CP-31398 has a pro-survival effect
To analyze the role of autophagy stimulation byGEM/CP-31398 drug
combination on cell proliferation and apoptosis, we treated both Panc1
and PaCa3 cell lines with the combined treatment in the absence or
presence of chloroquine (CQ) or 3-methyladenine (3-MA), the pharma-
cological inhibitors of autophagy. The results showed that apoptosis in-
duced by GEM/CP-31398 treatment was signiﬁcantly increased by the
addition of CQ or 3-MA in both cell lines (Fig. 7A). Consistently, despite
the non-cytotoxic concentrations of CQ or 3-MA (Suppl. Fig. 5A), they
both were able to reduce the formation of autophagosomes in the
GEM/CP-31398 treated cells (Suppl. Fig. 5B) and furthermore, to signif-
icantly sensitize both cell lines to the antiproliferative effect of GEM/CP-
31398 (Fig. 7B). Similar results have been obtained using a genetic
approach to inhibit autophagy. Indeed, the knock-down of Beclin1, a
proteinwith a pivotal role in the autophagicmachinery, by siRNA trans-
fection (Fig. 7C) signiﬁcantly increased cell growth inhibition stimulat-
ed by GEM/CP combined treatment (Fig. 7D). Together, these results
indicated that, at least in this cellular context, autophagy had a protec-
tive and pro-survival role and that a full effect of GEM/CP-31398 drug
combination was achieved when autophagy was inhibited.
4. Discussion
To date, many clinical trials have failed to demonstrate an improve-
ment in the overall survival of pancreatic cancer patients treated with
GEM in combinationwith different drugs. Extensive research is current-
ly focused on the identiﬁcation of novel potential therapeutic targets to
overcome GEM resistance of PDAC [35]. Accordingly, high-throughput
and proteomic tools are extensively used to unravel the early mecha-
nisms of pancreatic cancer onset and chemoresistance, as well as, to dis-
cover biomarkers to aid in prevention, prediction, and development of
personalized medicine for treatment of this neoplasm [36]. The p53
tumor suppressor protein is a master transcriptional regulator that con-
trols several key physiological pathways, such as cell cycle arrest, apo-
ptosis, senescence, DNA damage response and metabolism [37–39].
TP53 gene is mutated in more than 50% of inﬁltrating PDACs.A combinations.
CI50 DRI50 r
0.41 GEM: 8.9
CP: 1.8
0.95
0.51 GEM: 2.5
CP: 9.0
0.97
0.28 GEM: 26.5
RITA: 4.1
0.91
0.49 GEM: 11.3
RITA: 2.5
0.97
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Fig. 6. Effect of GEM and CP-31398 on apoptosis and autophagy. (A) Panc1 and PaCa3 cells
were seeded in 96-well plates, incubated overnight, and treated with 2.5 μMGEM and/or
20 μM CP-31398 for 48 h. Apoptosis was analyzed using annexinV binding assays.
*p b 0.05. (B) Cells were seeded in 96-well plates, incubated overnight, and treated with
1 μM GEM and/or 8 μM CP-31398 for 48 h. Autophagosome formation was assayed by
the incorporation ofmonodansylcadaverine (MDC)probe. *pb 0.05. (C) Cellswere seeded
in 100-mmdiameter culture dishes, incubated overnight, and treatedwith 5 μMGEMand/
or 40 μM CP-31398 for 48 h.Whole-cell extracts were processed for western blot analysis
of the autophagic marker LC3. GAPDH protein level in the same extract was used as a con-
trol loading.
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activation of p53 could lead to tumor stasis/regression even in the pres-
ence of multiple tumor-associated genetic alterations [40,41]. These
observations have paved the way for the identiﬁcation of small
molecules able to transform mp53 proteins in tumors into forms that
can perform wild-type p53 tumor suppressor functions in cancer cells
[42]. We have recently demonstrated that p53-reactivating small mole-
cules can signiﬁcantly reduce cell proliferation of both wt and mp53
PDAC cell lines, without having any effect on p53-null cancer cells [26]
. Here, we showed that GEM treatment stabilized mp53 (and its serin
15 phosphorylated form) in the nuclei, induced the expression of
mp53 cell cycle target genes (CdK1 and CCNB1; Figs. 1 and 2), and stim-
ulated pancreatic cancer cell resistance to GEM treatment (Fig. 3). Our
data is consistent with the observations that non-functional p53 affects
the sensitivity of cancer cells to GEM [43] and that restoration of p53
function by various approaches in tumors allows activation ofmolecular
pathways that improve the response to GEM [44,45]. Accordingly, some
studies demonstrated that exposure to GEM enhances the transcrip-
tional activity of p53 and that GEM-induced apoptosis in cancer cells
is mediated by a p53-dependent transcriptional activation of cell
death-related genes [46,47]. Here, we showed that the combined treat-
ment of PDAC cells with GEM and p53-reactivating molecules (CP-
31398 and RITA) synergistically inhibited cell proliferation in both wt
and mp53 tumor cells but not in p53-null cancer cells (Fig. 5 and
Suppl. Fig. 4). These results may be explained by the observations
that: i) inwt-p53 cells, p53-reactivatingmolecules can further stimulate
p53 activity induced by GEM; ii) in mp53 cells, these compounds can
stabilize a wt-like conformational status of p53 by modifying the mu-
tant conformation, enabling them to respond to GEM-mediated stimu-
lation; iii) in p53-null cells, the absence of the protein hampers the
effect of p53-reactivating molecules and their synergistic effect with
GEM. We also showed that combination GEM/CP-31398 or RITA drug
treatment increased the sensitivity of the cancer cells to minimum
GEM concentration, which in vivo can translate into decreased
chemotherapy-related side effects. The reduction of GEM concentration
in combined drug treatment approaches is much more pronounced in
mp53 PDAC cells than in wt p53 cells, suggesting that GEM resistance
in mp53 cells can efﬁciently be overcome by p53-reactivating mole-
cules. Our data showed that GEM/CP-31398 treatment was also able
to strongly induce p53 phosphorylation on Ser15 residue (Fig. 4),
which has been described to play a role in the regulation of p53-
mediated apoptosis [48]. Ser15 phosphorylation has been shown to re-
sult in the accumulation of p53 via the inhibition of its interaction with
MDM2 and degradation [49]. However, we did not observe any signiﬁ-
cant increase of the total level of p53 protein, suggesting that, at least
under these experimental condition, GEM/CP-31398 effect was not me-
diated by inhibition of the MDM2-p53 interaction.
Autophagy is amechanism that cells adopt following nutrient depri-
vation or stressful stimuli to remove proteins and organelles via lyso-
somal pathway, where they are degraded and recycled [50]. It has
been reported that autophagy can be stimulated by up-regulation of a
number of autophagy-related genes via a p53-mediated mechanism
[51]. However, the role of autophagy in cancer is still controversial,
mainly due to its dual function, which can protect cancer cells during
a stressful episode or promote cell death known as “autophagic cell
death” [52–54]. In this study, we also investigated the involvement of
autophagy in PDAC cells treated with GEM/CP-31398 combination.
Our results clearly showed that the antiproliferative effect of GEM/CP-
31398 treatment was paired with a strong autophagosome formation
(Fig. 6). This was further conﬁrmed by pharmacological and genetic in-
hibition of autophagy, which strongly enhanced apoptotic cell death by
GEM/CP-31398 treatment, indicating autophagy as a protective and sur-
vival mechanism for cancer cells. Our results are consistent with recent
studies describing that the autophagy inhibitor verteporﬁn, identiﬁed in
a screen for chemicals that prevent autophagosome formation and ap-
proved by FDA, enhanced the antitumor activity of GEM in a PDACmodel [55]. Remarkably, Yang S. et al. demonstrated that pancreatic
cancers have constitutively activated autophagy and a profound re-
quirement for this process, making them uniquely sensitive to autoph-
agy inhibition [56]. Additionally, Fijii et al. reported the clinico-
pathological signiﬁcance of autophagy in PDAC by demonstrating that
LC3 (an autophagy marker) positivity was correlated with shorter
disease-free and poor overall survival [57]. In this context, the role of
the p53 mutational status is still discussed. In an autochthonous
model of pancreatic cancer driven by oncogenic Kras and the stochastic
LOH of Tp53, Yang A. et al. elegantly demonstrated that autophagy has a
98 C. Fiorini et al. / Biochimica et Biophysica Acta 1853 (2015) 89–100critical role in pancreatic cancers and that inhibition of autophagy may
have clinical utility in the treatment of these tumors, independent of
p53 status [58]. On the other hand, Rosenfeldt et al. reported that the
p53 status can determine the role of autophagy in pancreatic cancer de-
velopment, demonstrating that the autophagy inhibitor chloroquine
can enhance tumor formation in mouse models lacking p53, while in
the presence of functioning wt p53, genetic ablation of autophagy canB
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Fig. 7. Role of autophagy in the antiproliferative effect of GEM/CP-31398 combination treatme
GEM plus 20 μM CP-31398 for 48 h in the absence or presence of 10 μM chloroquine (CQ) o
assay. *p b 0.05. (B) Cells were seeded in 96-well plates, incubated overnight, and treated wit
48 h in the absence or presence of 10 μM CQ or 2.5 mM 3MA. The following concentrations u
2); 200 nM GEM+ 1.6 μM CP (condition 3); 500 nM GEM+ 4 μM CP (condition 4); 1 μM GE
determined using the Crystal Violet colorimetric assay. (C) Panc1 cells were seeded in 60-mmd
or negative control siRNA for 24 h. Beclin1 expressionwas analyzed bywestern blot using whol
loading control. (D) Cellswere seeded in 96-well plates, incubated overnight, and transfectedwith
8 μM CP for a further 48 h. Cell proliferation was determined using the Crystal Violet colorimetrblock progression of pre-malignant lesions to high-grade pancreatic
intraepithelial neoplasia and PDAC [59].
In summary, we have provided a novel functional link between GEM
treatment, already used as conventional therapy in pancreatic adeno-
carcinoma, and autophagic inhibitors associated with p53-reactivating
molecules. Our data might contribute: a) to better deﬁne the molecular
events underlying GEM chemoresistance in mp53 pancreatic tumour0
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nt. (A) Cells were seeded in 96-well plates, incubated overnight, and treated with 2.5 μM
r 2.5 mM 3-methyladenine (3MA). Apoptosis was assessed using the annexin V binding
h six increasing concentrations of GEM/CP-31398 combination (1:8 ﬁxed molar ratio) for
sed were: 50 nM GEM + 0.4 μM CP (condition 1); 100 nM GEM+ 0.8 μM CP (condition
M + 8 μM CP (condition 5); 2 μM GEM+ 16 μM CP (condition 6). Cell proliferation was
iameter culture dishes, incubated overnight, and transfectedwith Beclin1 siRNA (siBECN1)
e-cell extracts and Beclin1 antibody. GAPDHprotein level in the same extractwas used as a
Beclin1 siRNAor negative control siRNA. Theday after, cellswere treatedwith 1 μMGEM+
ic assay. *p b 0.05.
99C. Fiorini et al. / Biochimica et Biophysica Acta 1853 (2015) 89–100cells and consequently to tailor more accurately target speciﬁcity and
b) to design therapeutic protocols for the use of autophagic inhibitors
to sensitize pancreatic adenocarcinoma cells to treatments with GEM
and p53-reactivating molecules.
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